AUA 2025: Focus on Bladder Cancer
Stay up-to-date with the latest research and clinical updates on bladder cancer from the AUA 2025 Annual Meeting.
Global shortages of BCG have led to the exploration of alternative therapies for HR non-muscle invasive bladder cancer.
Consolidative surgery after EVP shows feasibility and strong pathologic response rates in advanced urothelial carcinoma.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
Interim data may support the use of light-activated TLD-1433 photodynamic therapy for patients with BCG–unresponsive NMIBC.
N-803 plus BCG delivers sustained complete responses and high PFS in BCG-unresponsive bladder CIS, 2025 AUA data show.
Dr. Roberto Contieri presented on the safety, tolerability, and efficacy of neoadjuvant mitomycin C in patients with NMIBC.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.